UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...

Panelist discusses how urologists can benefit from adopting newer treatment modalities like aqua ablation for BPH, emphasizing its growing popularity, ease of learning, and efficiency in improving ...

The FDA will evaluate talazoparib and enzalutamide for mCRPC patients unselected for HRR gene alterations, expanding beyond HRR-positive cases. TALAPRO-2 trial data showed significant radiographic ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

Sasanlimab combined with BCG improved event-free survival in high-risk NMIBC patients, particularly those with CIS and T1 tumors. Subgroup analyses showed EFS benefits across different disease stages, ...

Prostate-specific membrane antigen (PSMA) expression in renal cell carcinoma (RCC) was an incidental finding but shows potential. Uncertainty regarding frequency of PSMA expression across RCC subtypes ...

Exploring the impact of ultra-sensitive PSA testing on treatment decisions for metastatic hormone-sensitive prostate cancer, enhancing patient outcomes and care efficiency. Dr Shore provided guidance ...

Paul E. Dato, MD, discusses how the absence of genetic alterations in the second case makes the patient ineligible for PARP inhibitor therapy until castration resistance develops, with focus remaining ...

Enzalutamide plus ADT significantly improves 5-year overall survival in mHSPC, with a 30% reduction in death risk compared to placebo plus ADT. The survival benefit of enzalutamide is consistent ...

Mechanism of Action: Nogapendekin alfa is an immunotherapy that combines a recombinant protein designed to stimulate the immune system with the aim of inducing a localized immune response against ...

A recent study by Moyer et al (2025) provides real-world data on the efficacy and safety of nadofaragene firadenovec in patients with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC).

Current imaging cannot reliably predict tumor biology or aggressiveness. Need for imaging techniques that can identify aggressive lesions requiring immediate intervention Comparison to advances in ...